Skip to main content
. 2013 Aug 2;5(9):1415–1430. doi: 10.1002/emmm.201302618

Figure 6. VEGFR3 is selectively and profoundly expressed in the EC of VSFs at the CTR and could be involved in EEVSF in a ligand independent manner during early pregnancy.

Figure 6

  • A. Representative images showing VEGFR3+ VSFs in the endometrium and VEGFR3+ lymphatic vessels (LV) in the myometrium of uteri at 6.5 and 8.5 dpc. Scale bars, 500 µm. UL, uterine lumen.
  • B. Images showing VEGF-C expression in the myometrium (Myo), and the MR, CTR and AMR of endometrium in uterus of VEGF-C+/LacZ mouse at 8.5 dpc. Scale bars, 100 µm.
  • C. Images showing CD105+ BVs in the uteri at 8.5 dpc treated with Fc and soluble VEGFR3 (sVEGFR3, 25 mg/kg). Scale bars, 500 µm.
  • D, E. Comparisons of CD105+ BVD (%) in the ULR, CTR and AMR, and numbers of different sized of VSFs in the CTR at 8.5 dpc treated with Fc and sVEGFR3. Each group, n = 4.